| review article | Q7318358 |
| scholarly article | Q13442814 |
| P356 | DOI | 10.1081/JAS-120018783 |
| P698 | PubMed publication ID | 12870839 |
| P2093 | author name string | Bruce M Prenner | |
| George Bensch | |||
| P2860 | cites work | Ligand-independent activation of the glucocorticoid receptor by beta2-adrenergic receptor agonists in primary human lung fibroblasts and vascular smooth muscle cells | Q28119034 |
| Montelukast added to inhaled beclomethasone in treatment of asthma. Montelukast/Beclomethasone Additivity Group | Q28377391 | ||
| Montelukast, a leukotriene receptor antagonist, reduces the concentration of leukotrienes in the respiratory tract of children with persistent asthma | Q28377400 | ||
| Comparison of inhaled salmeterol and oral zafirlukast in patients with asthma | Q28377487 | ||
| Onset of bronchodilation of budesonide/formoterol vs. salmeterol/fluticasone in single inhalers | Q31854727 | ||
| Advair: combination treatment with fluticasone propionate/salmeterol in the treatment of asthma | Q31928125 | ||
| Clinical equivalence of salmeterol/fluticasone propionate in combination (50/100 microg twice daily) when administered via a chlorofluorocarbon-free metered dose inhaler or dry powder inhaler to patients with mild-to-moderate asthma | Q32058604 | ||
| New combination therapies for asthma | Q32064196 | ||
| Subsensitivity of bronchodilator and systemic beta 2 adrenoceptor responses after regular twice daily treatment with eformoterol dry powder in asthmatic patients | Q33604886 | ||
| Randomised, placebo controlled trial of effect of a leukotriene receptor antagonist, montelukast, on tapering inhaled corticosteroids in asthmatic patients | Q33627353 | ||
| Systemic adverse effects of inhaled corticosteroid therapy: A systematic review and meta-analysis | Q33634936 | ||
| Regulation of beta-adrenergic receptors by "permissive" hormones: glucocorticoids increase steady-state levels of receptor mRNA. | Q33669474 | ||
| Salmeterol/fluticasone propionate combination | Q33684269 | ||
| Circadian rhythms in the pharmacokinetics and clinical effects of beta-agonist, theophylline, and anticholinergic medications in the treatment of nocturnal asthma | Q33747962 | ||
| Salmeterol tachyphylaxis in steroid treated asthmatic subjects | Q33775495 | ||
| The distal airways: are they important in asthma? | Q33810770 | ||
| Meta-analysis of increased dose of inhaled steroid or addition of salmeterol in symptomatic asthma (MIASMA). | Q33922403 | ||
| Safety of inhaled and intranasal corticosteroids: lessons for the new millennium | Q33983915 | ||
| The anti-inflammatory profile of inhaled corticosteroids combined with salmeterol in asthmatic patients | Q34074333 | ||
| Inhaled salmeterol/fluticasone propionate combination: a review of its use in persistent asthma | Q34112937 | ||
| Nocturnal asthma uncontrolled by inhaled corticosteroids: theophylline or long-acting beta2 agonists? | Q34212920 | ||
| Scientific rationale for inhaled combination therapy with long-acting beta2-agonists and corticosteroids | Q34529658 | ||
| Addition of salmeterol versus doubling the dose of fluticasone propionate in patients with mild to moderate asthma | Q35532986 | ||
| Decreased Beta-Adrenergic Receptors on Polymorphonuclear Leukocytes after Adrenergic Therapy | Q39209687 | ||
| A comparison of two long-acting beta-agonists, oral bambuterol and inhaled salmeterol, in the treatment of moderate to severe asthmatic patients with nocturnal symptoms. The French Bambuterol Study Group | Q39436795 | ||
| The complementary role of glucocorticosteroids and long-acting beta-adrenergic agonists | Q39447522 | ||
| Salmeterol in two different doses in the treatment of nocturnal bronchial asthma poorly controlled by other therapies | Q39480041 | ||
| Reduced β-adrenergic receptor concentrations in ageing man | Q40093721 | ||
| Asthma in the elderly patient | Q41461180 | ||
| Potential masking effects of salmeterol on airway inflammation in asthma | Q42539849 | ||
| Zafirlukast improves asthma control in patients receiving high-dose inhaled corticosteroids | Q43505948 | ||
| The effect of salmeterol on markers of airway inflammation following segmental allergen challenge | Q43562544 | ||
| Effective control of asthma with hydrofluoroalkane flunisolide delivered as an extrafine aerosol in asthma patients | Q43813371 | ||
| Salmeterol/Fluticasone combination inhaler: a new, effective and well tolerated treatment for asthma | Q46957858 | ||
| Inhaled corticosteroid reduced lamina reticularis of the basement membrane by modulation of insulin-like growth factor (IGF)-I expression in bronchial asthma | Q47914780 | ||
| Salmeterol vs theophylline: sleep and efficacy outcomes in patients with nocturnal asthma | Q48759578 | ||
| Effect of inhaled formoterol and budesonide on exacerbations of asthma. Formoterol and Corticosteroids Establishing Therapy (FACET) International Study Group | Q49092631 | ||
| Montelukast or salmeterol combined with an inhaled steroid in adult asthma: design and rationale of a randomized, double-blind comparative study (the IMPACT Investigation of Montelukast as a Partner Agent for Complementary Therapy-trial). | Q53516366 | ||
| Nocturnal asthma: effect of salmeterol on quality of life and clinical outcomes. | Q53556141 | ||
| Long-term effects of budesonide or nedocromil in children with asthma. | Q53809666 | ||
| A bolus of inhaled budesonide rapidly reverses airway subsensitivity and beta2-adrenoceptor down-regulation after regular inhaled formoterol. | Q53917067 | ||
| NO in Exhaled Air of Asthmatic Children Is Reduced by the Leukotriene Receptor Antagonist Montelukast | Q57638323 | ||
| Exhaled nitric oxide before and after montelukast sodium therapy in school-age children with chronic asthma: A preliminary study | Q58387531 | ||
| The long‐acting β2‐agonist salmeterol xinafoate: effects on airway inflammation in asthma | Q59685194 | ||
| Further studies on the chronotherapy of asthma with inhaled steroids: The effect of dosage timing on drug efficacy | Q63740333 | ||
| Epidemiology of nocturnal asthma | Q68461374 | ||
| Nedocromil sodium is more effective than cromolyn sodium for the treatment of chronic reversible obstructive airway disease | Q70467407 | ||
| Comparison of addition of salmeterol to inhaled steroids with doubling of the dose of inhaled steroids | Q71078827 | ||
| Inhaled corticosteroids do not prevent the development of tolerance to the bronchoprotective effect of salmeterol | Q71089909 | ||
| Bronchodilator subsensitivity to salbutamol after twice daily salmeterol in asthmatic patients | Q71897448 | ||
| An inhaled glucocorticoid does not prevent tolerance to the bronchoprotective effect of a long-acting inhaled beta 2-agonist | Q71906908 | ||
| Added salmeterol versus higher-dose corticosteroid in asthma patients with symptoms on existing inhaled corticosteroid. Allen & Hanburys Limited UK Study Group | Q72684559 | ||
| High-dose nedocromil sodium as an addition to inhaled corticosteroids in the treatment of asthma | Q72837610 | ||
| Fluticasone propionate/salmeterol combination provides more effective asthma control than low-dose inhaled corticosteroid plus montelukast | Q73288226 | ||
| Oral montelukast compared with inhaled salmeterol to prevent exercise-induced bronchoconstriction. A randomized, double-blind trial. Exercise Study Group | Q73376058 | ||
| Salmeterol/fluticasone propionate (50/500 microg) in combination in a Diskus inhaler (Seretide) is effective and safe in the treatment of steroid-dependent asthma | Q73398082 | ||
| Combined salmeterol 50 microg and fluticasone propionate 250 microg in the diskus device for the treatment of asthma | Q73445017 | ||
| Non-pulmonary effects induced by the addition of formoterol to budesonide therapy in patients with mild or moderate persistent asthma | Q73516637 | ||
| Systemic corticosteriod rapidly reverses bronchodilator subsensitivity induced by formoterol in asthmatic patients | Q73528586 | ||
| A comparison of low-dose inhaled budesonide plus theophylline and high-dose inhaled budesonide for moderate asthma | Q73848777 | ||
| Salmeterol and fluticasone propionate combined in a new powder inhalation device for the treatment of asthma: a randomized, double-blind, placebo-controlled trial | Q73900956 | ||
| Salmeterol/fluticasone propionate (50/100 microg) in combination in a Diskus inhaler (Seretide) is effective and safe in children with asthma | Q74098152 | ||
| Salmeterol/fluticasone propionate combination therapy 50/250 microg twice daily is more effective than budesonide 800 microg twice daily in treating moderate to severe asthma | Q74112300 | ||
| Comparison of addition of theophylline to inhaled steroid with doubling of the dose of inhaled steroid in asthma | Q74287040 | ||
| Hydrofluoroalkane-134a beclomethasone dipropionate, 400 microg, is as effective as chlorofluorocarbon beclomethasone dipropionate, 800 microg, for the treatment of moderate asthma | Q74459012 | ||
| Effect of salmeterol treatment on nitric oxide level in exhaled air and dose-response to terbutaline in children with mild asthma | Q74683402 | ||
| Salmeterol and fluticasone propionate (50/250 microg) administered via combination Diskus inhaler: as effective as when given via separate Diskus inhalers | Q77321212 | ||
| The addition of salmeterol to fluticasone propionate versus increasing the dose of fluticasone propionate in patients with persistent asthma. Salmeterol Study Group | Q77397430 | ||
| Hydrofluoroalkane-134a beclomethasone dipropionate extrafine aerosol provides equivalent asthma control to chlorofluorocarbon beclomethasone dipropionate at approximately half the total daily dose | Q77670988 | ||
| Montelukast versus salmeterol in patients with asthma and exercise-induced bronchoconstriction. Montelukast/Salmeterol Exercise Study Group | Q78247436 | ||
| P433 | issue | 4 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 431-444 | |
| P577 | publication date | 2003-06-01 | |
| P1433 | published in | Journal of Asthma | Q2603603 |
| P1476 | title | Combination therapy: appropriate for everyone? | |
| P478 | volume | 40 |
Search more.